Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases

Journal of Cutaneous Pathology

Volumn 45, Issue 1, 2018, Pages 48-53

  Everett, Ashlyn S ^a   Pavlidakey, Peter G ^b   Contreras, Carlo M ^c   De Los Santos, Jennifer F ^a   Kim, Ju Y ^d   McKee, Svetlana B ^e   Kaufman, Howard L ^f   Conry, Robert M ^e  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d A Novartis Subsidiary Inc   (United States)

^e Heerskink School of Medicine   (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

dermatitis; granuloma; melanoma; oncolytic viral immunotherapy; talimogene laherparepvec

Indexed keywords

AGED; CASE REPORT; CHEMICALLY INDUCED; CHRONIC DISEASE; DERMATITIS; DRUG ERUPTION; GRANULOMA; HUMAN; MALE; MELANOMA; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; PATHOLOGY; SECONDARY; SKIN TUMOR; TUMOR RECURRENCE;

AGED; CHRONIC DISEASE; DERMATITIS; DRUG ERUPTIONS; GRANULOMA; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOLYTIC VIROTHERAPY; SKIN NEOPLASMS;

EID: 85032212444     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.13048     Document Type: Article

References (9)

1. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
2. Bommareddy PK, Patel A, Hossain S, et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18:1–15.
3. Harrington KJ, Andtbacka RH, Collichio F, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016;9:7081–7093.
4. Wynn AA, Miyakawa K, Miyata E, et al. Role of granulocyte/macrophage colony-stimulating factor in zymocel-induced hepatic granuloma formation. Am J Pathol. 2001;158:131–145.
5. Szeliga J, Daniel DS, Yang CH, et al. Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis. Tuberculosis (Edinb). 2008;88:7–20.
6. Noh TW, Park SH, Kang YS, et al. Morphea developing at the site of healed herpes zoster. Ann Dermatol. 2011;23:242–245.
7. Ferenczi K, Rosenberg AS, McCalmont TH, et al. Herpes zoster granulomatous dermatitis: histopathologic findings in a case series. J Cutan Pathol. 2015;42:739–745.
8. Garrido MC, Gutierrez C, Riveiro-Falkenbach E, et al. BRAF inhibitor-induced antitumoral granulomatous dermatitis eruption in advanced melanoma. Am J Dermatopathol. 2015;37:795–798.
9. Sinha R, Larkin J, Gore M, et al. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Br J Dermatol. 2015;173:1024–1031.